Oral Immunotherapy for Peanut Allergy (PMIT)

Completed · Phase 2 · Has a placebo group

Conditions studied: Food Hypersensitivity

In brief

The purpose of this study is to determine if mucosal peanut immunotherapy will make subjects who have peanut allergy less allergic and induce changes in their immune system.

Key facts

Study ID

NCT00597675

Run by

University of North Carolina, Chapel Hill

People needed

10

Starts

2007-03-01

Expected to finish

2014-06-01

Last updated by the study team

2018-03-27

Who can join

Age: 1 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject between 1 and 18 years of age
• EITHER history of significant clinical symptoms occurring within 60 minutes after ingesting peanuts greater than 6 months ago AND peanut specific IgE >15 kU/L
• OR history of significant clinical symptoms occurring within 60 minutes after ingesting peanuts within the past 6 months AND peanut specific IgE > 7 kU/L
• A family that will be able to be compliant with all study visits
• All females of child bearing age must be using appropriate birth control

You may not qualify if…

• Subjects with a history of severe, anaphylaxis to peanut
• Medical history that would prevent a double blind placebo controlled oral food challenge (DBPCFC/OFC) to peanut
• Unable to cooperate with challenge procedures or unable to be reached by telephone for follow-up
• Diagnosed oat allergy
• Pregnancy or lactation

Where it is running

• University of Arkansas Medical Center — Little Rock, Arkansas, United States
• University of North Carolina — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.